CN105169203B - A kind of Fructus Amomi extract and application thereof - Google Patents
A kind of Fructus Amomi extract and application thereof Download PDFInfo
- Publication number
- CN105169203B CN105169203B CN201510617335.2A CN201510617335A CN105169203B CN 105169203 B CN105169203 B CN 105169203B CN 201510617335 A CN201510617335 A CN 201510617335A CN 105169203 B CN105169203 B CN 105169203B
- Authority
- CN
- China
- Prior art keywords
- fructus amomi
- volatile oil
- amomum fruit
- extract
- water extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000000341 volatile oil Substances 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 238000000605 extraction Methods 0.000 claims abstract description 5
- 238000001256 steam distillation Methods 0.000 claims abstract description 5
- 241001127714 Amomum Species 0.000 claims description 23
- 235000013399 edible fruits Nutrition 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 15
- 239000012153 distilled water Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 208000008589 Obesity Diseases 0.000 abstract description 11
- 102000019280 Pancreatic lipases Human genes 0.000 abstract description 11
- 108050006759 Pancreatic lipases Proteins 0.000 abstract description 11
- 229940116369 pancreatic lipase Drugs 0.000 abstract description 11
- 239000002158 endotoxin Substances 0.000 abstract description 10
- 235000020824 obesity Nutrition 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 210000002966 serum Anatomy 0.000 abstract description 5
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 230000001603 reducing effect Effects 0.000 abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 3
- 235000009200 high fat diet Nutrition 0.000 abstract description 3
- 230000006698 induction Effects 0.000 abstract description 3
- 230000035622 drinking Effects 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 230000010354 integration Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000019626 lipase activity Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- -1 oral solution Substances 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 229960001243 orlistat Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000019637 Infantile Diarrhea Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 125000000185 sucrose group Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- VJOUUGUSJOHNRQ-UHFFFAOYSA-N OC[Na] Chemical compound OC[Na] VJOUUGUSJOHNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 101000800134 Rattus norvegicus Thyroglobulin Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of purposes of fructus amomi water extract and volatile oil in the drug of preparation weight-reducing and reducing blood lipid.It is that fructus amomi is crushed, is impregnated, is decocted, obtains water extract；Or fructus amomi (Amomun villosum Lour) is crushed, is impregnated, extraction by steam distillation collection volatile oil.The slimming medicine of acquisition uses the raw material of integration of drinking and medicinal herbs, obesity with control high fat diet induction, alleviates the hyperlipidemia under obese state, inhibits the high serum endotoxin state under obese state, the effect for inhibiting pancreatic lipase, can reach healthy fat reducing purpose very well.
Description
Technical field
The present invention relates to drugs and field of health care products, and in particular to a kind of Fructus Amomi extract and application thereof.
Background technique
When obesity (obescity) refers to human body heat taken in more than consumption of calorie, extra heat is in the form of fatty
Storage in vivo, causes body fat accumulation excessive and (or) abnormal distribution, and then causes one kind of weight gain multifactor slow
Property metabolic disease.It is counted according to WHO, existing global obesity alreadys exceed 300,000,000 people, 1,100,000,000 people's overweights, because " eating " causes a disease
Or even dead number has been higher than because of hungry dead number.The obesity patient of China is listed in the whole world more than seven million peoples
Obesity disease incidence ranking list the 10th.Relevant expert predicts in coming 10 years that the obese people in China can exceed that 200,000,000.Always
It is well known, the diseases such as obesity and cardiovascular and cerebrovascular disease, hypertension, diabetes B, blood fat disorder, sleep apnea syndrome
The occurrence and development of disease have close relationship.It is more severe, obesity can cause other organs for example the heart, blood vessel, lung it is secondary
Disease, and life expectancy can be shortened.Show that the average life span of obese people is significantly below the crowd of normal type according to investigations.Cause
This obesity is cited as the risk factor of health, constitutes a serious threat to human health and social development, and research and development are corresponding pre-
Anti- treatment means become urgent need.However, currently on the market common diet products be mainly appetite control class, cathartic,
Diuretics, increase metabolism class etc., though solve problem of obesity in the short time, because many products contain the ingredient that is harmful to the human body,
Actually it is less useful for human health.Therefore the highly desirable diet products for obtaining a kind of excellent effect.
As one of China " four great Nan medicines ", have more than 1300 years medicinal and edible goes through fructus amomi (Amomi Fructus)
History.Fructus amomi is Zingiber Amomum herbaceos perennial, and warm-natured, acrid flavour has dampness elimination appetizing, warming spleen and stopping diarrha, regulating the flow of vital energy and preventing miscarriage etc.
Effect is the common medicine of Chinese traditional treatment gastrointestinal disease.Modern pharmacological studies have shown that the principle active component in fructus amomi includes acetic acid dragon
The volatile materials such as brain ester, camphor, limonene, borneol, having improves stomach and intestine function, analgesic, antidiarrheal, point for promoting digestive juice
It secretes, reduces blood lipid, adjusts the effects of intestinal flora.Fructus amomi as common medicinal and edible medicinal material by clinical practice all the year round with
Modern research shows that the medicinal material has toxic side effect small, the significant advantage of drug effect.
Many diet products have the problem that side effect is big and adverse reaction is more at present, thus regarding to the issue above we
Wish can to provide that a kind of toxic side effect is small, the more excellent natural fat-reducing product of fat-reducing effect.
Summary of the invention
The purpose of the present invention is: overcome the problems, such as that many diet products side effects are big at present and adverse reaction is more, provides
A kind of toxic side effect is small, fat-reducing effect more excellent natural fat-reducing product fructus amomi water extract and amomum fruit volatile oil.
It is a further object to provide a kind of methods that preparation is made by above-mentioned diet products.
The technical solution that the present invention solves the technical problem is:
The preparation method of fructus amomi water extract adds distilled water the following steps are included: precision weighs 50-150g after fructus amomi is crushed
250-1000ml impregnates half an hour, is cooked by slow fire after boiling 5-10 minutes, filtering liquid medicine obtains filtrate A and dregs of a decoction A；Dregs of a decoction A adds steaming
Distilled water decocts 5-10 minutes again, and filtering liquid medicine obtains liquor B and dregs of a decoction B；Dregs of a decoction B adds distilled water to decoct again 5-10 minutes, filtering
Medical fluid obtains liquor C；Merging filtrate A, B, C are concentrated, freeze-drying, as fructus amomi water extract.
The preparation method of amomum fruit volatile oil is the following steps are included: precision weighs 50-150g and is placed in round bottom after fructus amomi is crushed
In flask, add distilled water 200-800ml, impregnate 0.5-1 hours, using extraction by steam distillation 5-10h, collects volatile oil,
As amomum fruit volatile oil.
The present invention also provides the preparations containing Fructus Amomi extract, by Fructus Amomi extract and pharmaceutically acceptable carrier group
At.
The preparation is tablet, capsule or granule, oral solution, injection.
The pharmaceutically acceptable carrier refers to the common pharmaceutical carrier of pharmaceutical field, selected from surfactant, filling
One or more of agent, suspending agent, solvent, corrigent, adhesive, disintegrating agent, wetting agent or lubricant.
The filler is selected from sucrose, dextrin, lactose, mannitol, starch, xylitol, glucose sugar etc.；
Described adhesive is selected from alginates, starch, dextrin, gelatin or polyvinylpyrrolidone etc.；
The disintegrating agent is selected from Sodium Hydroxymethyl Stalcs, low-substituted hydroxypropyl cellulose, microcrystalline cellulose or coach's methylol
Sodium cellulosate；
The lubricant is selected from polyethylene glycol, sodium bicarbonate, superfine silica gel powder, stearic acid or magnesium stearate；
The suspending agent is selected from cellulose, beeswax, solid polyethylene glycol or superfine silica gel powder；
The wetting agent is selected from Tween-80, glycerol, soft phosphatide；
The solvent is selected from glycerol, propylene glycol, vegetable oil, liquid polyethylene glycol or ethyl alcohol；
The surfactant is selected from stearic acid, eicosyl benzene sulfonic acid sodium salt, polysorbate or fatty acid sorbitan；
The corrigent is selected from sucrose, essence, citric acid, saccharin sodium or Aspartame.
Beneficial effects of the present invention:
The slimming drugs use the raw material of integration of drinking and medicinal herbs, have the obesity of control high fat diet induction, alleviate under obese state
Hyperlipidemia, inhibit obese state under high serum endotoxin state, inhibit the effect of pancreatic lipase, can reach very well strong
Health fat reducing purpose.
Detailed description of the invention
Influence of Fig. 1 fructus amomi difference extract to weight
Wherein, Infantile diarrhea: Golden Bifid (GLB)
Amomum fruit volatile oil: Volatile Oild from Fructus Amomi (VOA)
Fructus amomi water extract: Water extract from Fructus Amomi (WEA)
(VOA.H) high dose amomum fruit volatile oil
(VOA.M) middle dosage amomum fruit volatile oil
(VOA.L) low dosage amomum fruit volatile oil
(WEA.H) high dose fructus amomi water extract
(WEA.M) middle dosage fructus amomi water extract
(WEA.L) low dosage fructus amomi water extract
Influence of Fig. 2 fructus amomi difference extract to weight ratio of ingesting
Influence of Fig. 3 fructus amomi difference extract to triglycerides (TG)
Influence of Fig. 4 fructus amomi difference extract to total cholesterol (TC)
The influence of Fig. 5 fructus amomi difference extract induced by endotoxin (LPS)
Fig. 6 fructus amomi difference extract is in vitro to the influence of pancreatic lipase activity
Compared with normal group,*P < 0.05,**P < 0.01,***p<0.001
Compared with model group,#P < 0.05,##P < 0.01,###p<0.001
Specific embodiment
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.In the following examples, the experimental methods for specific conditions are not specified, usually according to conventional strip
Part or according to the normal condition proposed by manufacturer.Unless otherwise stated, otherwise all percentage, ratio, ratio or number is pressed
Poidometer.
Unless otherwise defined, it anticipates known to all professional and scientific terms as used herein and one skilled in the art
Justice is identical.In addition, any method similar to or equal to what is recorded and material can be applied to the method for the present invention.Wen Zhong
The preferred implement methods and materials are for illustrative purposes only.
Embodiment 1: fructus amomi water extract granule preparation
1 extracting method: it chooses Yunnan and introduces a fine variety Fructus Amomi (Amomun villosum Lour), precision weighs after crushing
200g adds distilled water 1000ml to impregnate half an hour, 10 minutes is cooked by slow fire after boiling, filtering liquid medicine.The dregs of a decoction add distilled water to decoct again
10 minutes, filtering liquid medicine, the dregs of a decoction added distilled water to decoct again 5 minutes, merged filtrate three times, were concentrated, and freeze-drying, as fructus amomi water mentions
Object.
2 preparations: fructus amomi water extract 50g plus starch about 110g, essence about 10g progressively increase uniformly mixed according to equivalent, granulation,
Packing is to get granule, and 5g/ bags, about 30 bags.
Embodiment 2: the preparation of amomum fruit volatile oil granule
1 extracting method: it chooses Yunnan and introduces a fine variety Fructus Amomi (Amomun villosum Lour), precision weighs after crushing
200g is set in a round bottom flask, adds distilled water 1200ml, is impregnated 1 hour, using extraction by steam distillation 10h, collects volatilization
Oil.
2 preparations: amomum fruit volatile oil 50g plus sucrose about 100g, dextrin about 10g progressively increase uniformly mixed according to equivalent, granulation,
Packing is to get granule, and 5g/ bags, about 30 bags.
Embodiment 3: the preparation of fructus amomi volatilization oil capsule
1 extracting method: it chooses Yunnan and introduces a fine variety Fructus Amomi (Amomun villosum Lour), precision weighs after crushing
200g is set in a round bottom flask, adds distilled water 1200ml, is impregnated 1 hour, using extraction by steam distillation 10h, collects volatilization
Oil.
2 preparations: capsule body is inserted into capsule board, volatile oil 50g made from method 1 is placed on capsule board, is gently struck
Dynamic capsule board, falls into medicinal powder in capsule shells, until capsule cap is put on after all filling medicinal powder in whole capsule shells, it is 0.5g/, total
100.
Embodiment 4: pharmacological evaluation
(1) fructus amomi is to the loss of weight of obese rat, lipid-loweringing and the effect for dropping serum endotoxin
Experiment uses SD rat 90, sets up normal group, model group, amomum fruit volatile oil (preparation of embodiment 2) (VOA) extract separately
Basic, normal, high dosage (4,8,16mg/kg) administration group, fructus amomi water extract (preparation of embodiment 1) (WEA) basic, normal, high dosage (24,
48,96mg/kg) administration group, probiotics Infantile diarrhea (GLB) positive controls (450mg/kg), except for the normal group, each group feeding are high
Rouge feed (lard 10%, yolk 10%, cholesterol 1%, basal feed 79%) to experiment terminates.Body is recorded during experiment daily
Weight, food-intake；Blood is taken on an empty stomach to the intraocular corner of the eyes of all rats every two weeks, each every amount for taking blood is about 1.5-2ml.
For taken blood with high speed desktop refrigerated centrifuge with the revolving speed of 10000r/min, 4 DEG C of centrifugation 15min take supernatant
Using triglyceride reagent box (GOP-POD method), total cholesterol kit (GOP-POD method) detection serum triglyceride (TG),
The content of total cholesterol (TC).
Take hepatic portal quiet using disposal vacuum venous blood collection pipe with chloraldurate solution anesthetized rat after testing 12 weeks
Arteries and veins blood, 2000r/min are centrifuged 10min, take upper plasma, detect gut derived exndotoxin (LPS) content using reagents.
As shown in Figure 1, high lipid food gives different fructus amomi water extracts while feeding SD rat, rat can effectively reduce
TG, TC content in weight and blood, while fructus amomi group food ration and model group are close, but weight gain is unobvious, weight of ingesting
Than high.It is wherein the most significant to rat body weight, TG, TC reducing effect with amomum fruit volatile oil extract.It is big that high lipid food feeds SD
After mouse 12 weeks, the content conspicuousness of model group LPS is increased, and fructus amomi water extract group inhibits the raising of LPS to a certain extent,
In it is the most significant with amomum fruit volatile oil inhibitory effect.The results show that (the latter's effect is more prominent for fructus amomi water extract and amomum fruit volatile oil
Out), the obesity of high fat diet induction can be obviously controlled, and the hyperlipidemia under obese state can be alleviated, can inhibit simultaneously
High serum endotoxin state under obese state.
(2) external inhibitory activity of the fructus amomi to pancreatic lipase
Pass through the body inhibited to amomum fruit volatile oil, water extract and positive drug orlistat (orlistat) to lipase active
Outer experiment evaluates amomum fruit volatile oil extract and water extract to pancreatic lipase activity using triglyceride release oleic acid as index
Effect.
Prepare 300units/mL pancreatic lipase solution.Fat emulsion is made referring to existing report method, is accurately weighed
80mg olein, 10mg lecithin, 5mg cholyltaurine are placed in the small revolving bottle of vigour, 60 DEG C of water bath methods.Add
The 0.1mol/Lde Tris- hydrochloric acid solution (PH7.0) of 9mL, ultrasonication 5min keep its fully emulsified.Finally in reactant
100uL fat emulsion, the pancreatic lipase solution of 50uL and the water of 100uL are added in system, this is blank control；In addition it reacts
Amomum fruit volatile oil extracting solution, water extract and the positive drug of 100uL various concentration are added in pipe, is experimental group.All centrifuge tubes in
37 DEG C of constant-temperature incubation 30min, after reaction, by specification operation, the fat discharged using free fatty acid kit measurement
Acid content, every sub-sampling 3 times are averaged expression enzyme activity, draw fructus amomi water extract and orlistat to pancreatic lipase activity
Suppression curve.
As shown in fig. 6, ordinate is the relative activity percentage of pancreatic lipase using abscissa as fructus amomi difference extract concentration
Number, it is seen that amomum fruit volatile oil and water extract have inhibiting effect to pancreatic lipase, and there are dosage effects, wherein being volatilized with fructus amomi
Oily inhibitory effect is preferable.It can be seen that amomum fruit volatile oil and water extract can by inhibiting intestinal fat enzyme to decomposition fatty in food,
To inhibit the synthesis of TG, TC, and then lose weight.
Experimental data of the invention can refer to the following table 1-4 in addition to Fig. 1-6.
1 fructus amomi difference extract of table to rat body weight influence (g,N=10)
Continued 1
Compared with normal group,*P < 0.05,**P < 0.01,***p<0.001
Compared with model group,#P < 0.05,##P < 0.01,###p<0.001
2 fructus amomi difference extract of table to rat ingest weight ratio influence (%,N=10)
Continued 2
3 fructus amomi difference extract of table to rat TG, TC (mmol/L,N=10) and LPS (EU,N=10)
The influence of content
Continued 3
Compared with normal group,*P < 0.05,**P < 0.01,***p<0.001
Compared with model group,#P < 0.05,##P < 0.01,###p<0.001
4 fructus amomi difference extract of table in vitro to the influence of pancreatic lipase activity (%,N=10)
The foregoing is merely illustrative of the preferred embodiments of the present invention, the substantial technological content model being not intended to limit the invention
It encloses, substantial technological content of the invention is broadly defined in the scope of the claims of application, any technology that other people complete
Entity or method also or a kind of equivalent change, will if identical with defined in the scope of the claims of application
It is considered as being covered by among the scope of the claims.
Claims (1)
1. amomum fruit volatile oil is preparing the application in slimming medicine, the preparation side of the amomum fruit volatile oil as sole active agent
Method are as follows: choose Yunnan and introduce a fine variety Fructus Amomi Amomun villosum Lour, precision weighs 200g and is placed in round-bottomed flask after crushing
In, add distilled water 1200ml, impregnate 1 hour, using extraction by steam distillation 10h, collects volatile oil；The drug is fructus amomi
Volatile oil granule, the amomum fruit volatile oil granule the preparation method comprises the following steps: above-mentioned amomum fruit volatile oil 50g, plus sucrose 100g, paste
Smart 10g progressively increases uniformly mixed according to equivalent, and granulation dispenses to get granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510617335.2A CN105169203B (en) | 2015-09-25 | 2015-09-25 | A kind of Fructus Amomi extract and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510617335.2A CN105169203B (en) | 2015-09-25 | 2015-09-25 | A kind of Fructus Amomi extract and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105169203A CN105169203A (en) | 2015-12-23 |
| CN105169203B true CN105169203B (en) | 2019-10-29 |
Family
ID=54891951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510617335.2A Expired - Fee Related CN105169203B (en) | 2015-09-25 | 2015-09-25 | A kind of Fructus Amomi extract and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105169203B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105999022B (en) * | 2016-05-03 | 2019-10-25 | 劲牌生物医药有限公司 | A method of amomum fruit volatile oil, fructus amomi flavones and fructus amomi polysaccharide are extracted using fructus amomi |
| CN106943564B (en) * | 2017-04-07 | 2020-07-10 | 云南中医学院 | Fructus amomi volatile oil soft capsule for relieving intestinal mucosa injury caused by chemotherapy |
| CN107307399A (en) * | 2017-05-23 | 2017-11-03 | 广州市高纤宝健康食品有限公司 | A kind of preparation method and application of the composition of digestive integration of drinking and medicinal herbs |
| KR101952644B1 (en) * | 2017-09-21 | 2019-05-23 | 국가식품클러스터지원센터 | The Inhibitory Obesity Effects of Amomum vilosum Loureiro Extracts and Composition Containing the Extract as Effective Ingredient |
| KR101865825B1 (en) | 2017-09-27 | 2018-06-08 | 에버웰테크놀로지 주식회사 | Heater including carbon felt and method for manufacturing the same |
| CN112608795B (en) * | 2020-11-26 | 2023-11-07 | 福建中特药业有限公司 | Fructus amomi leaf oil and water extraction-low-temperature pressure transformation extraction process method thereof |
| CN113318085B (en) * | 2021-06-07 | 2022-11-25 | 云南中医药大学 | Fructus amomi tablet for improving vomiting of pregnancy reaction and preparation method thereof |
| CN116349817A (en) * | 2023-04-07 | 2023-06-30 | 漳州卫生职业学院 | Fructus amomi solid beverage and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104351895A (en) * | 2014-10-24 | 2015-02-18 | 杨兰钦 | Spring and summer plant beverage |
| CN104435973A (en) * | 2014-11-11 | 2015-03-25 | 覃海兰 | Traditional Chinese medicine formula for losing weight |
| CN104784615A (en) * | 2015-03-26 | 2015-07-22 | 哈尔滨医科大学 | Traditional Chinese medicine composition for preventing and treating hyperlipidaemia, as well as preparation method and application of traditional Chinese medicine composition |
-
2015
- 2015-09-25 CN CN201510617335.2A patent/CN105169203B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104351895A (en) * | 2014-10-24 | 2015-02-18 | 杨兰钦 | Spring and summer plant beverage |
| CN104435973A (en) * | 2014-11-11 | 2015-03-25 | 覃海兰 | Traditional Chinese medicine formula for losing weight |
| CN104784615A (en) * | 2015-03-26 | 2015-07-22 | 哈尔滨医科大学 | Traditional Chinese medicine composition for preventing and treating hyperlipidaemia, as well as preparation method and application of traditional Chinese medicine composition |
Non-Patent Citations (2)
| Title |
|---|
| "砂仁、红枣、荔枝草及细本山葡萄等水萃物对调节血脂及肠道保健之探讨";黄雅玲;《中兴大学食品暨应用生物科技学系所学位论文》;20081231;"中文摘要"和"2.2.1 Preparation of plant extract samples" * |
| "砂仁挥发油的提取工艺";唐灿等;《华西药学杂志》;20080220;第23卷(第1期);"摘要"和"1.1仪器与材料" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105169203A (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105169203B (en) | A kind of Fructus Amomi extract and application thereof | |
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN104288345A (en) | A traditional Chinese medicine composition assisting blood lipid reduction and a preparing method thereof | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN102526478A (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| JP2011032217A (en) | Fat absorption inhibitor | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN108112992A (en) | A kind of functional medicine nutrition loss of weight formula and method | |
| WO2006017157A1 (en) | Weight loss composition | |
| CN102366094A (en) | Fat-reducing and hypolipemic health food | |
| CN104027494A (en) | Traditional Chinese medicinal composition with effects of delaying senescence and protecting health | |
| CN110051817A (en) | A kind of Chinese traditional medicine composition and its application reducing uric acid | |
| WO2019100843A1 (en) | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor | |
| CN111281902A (en) | Application of lithocarpus litseifolius or active extract thereof | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| CN109316565B (en) | Blood fat reducing composition and preparation method and application thereof | |
| CN104055115B (en) | A kind of health products containing agate coffee, the stem of noble dendrobium and Panax Japonicus Var. Major and preparation method thereof | |
| CN103181557A (en) | Nutritious food with slimming function and preparation method thereof | |
| CN105733880A (en) | Composite hazelnut wine brewed from hazelnut meal | |
| CN104971065A (en) | New application of theacrine in promotion of fat burning | |
| CN105193993B (en) | A kind of Chinese medicine composition with blood fat reducing function and preparation method thereof and purposes | |
| CN107595866A (en) | A kind of pharmaceutical preparation for treating diabetes | |
| CN106581142A (en) | Compound traditional Chinese medicine composition capable of regulating blood fat and purpose thereof | |
| CN109820913A (en) | The purposes and soft capsule of Zanthoxylum essential oil or Tengjiao oil | |
| CN104095868B (en) | A kind of pharmaceutical composition and pharmaceutical applications thereof improving sugar tolerance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191029 |